Markets

Alnylam (ALNY) Reports Positive Interim Data on ALN-PCSsc

Alnylam Pharmaceuticals, Inc.ALNY and The Medicines Company MDCO announced positive interim results from the ongoing phase I study on ALN-PCSsc for the treatment of patients with hypercholesterolemia. ALN-PCSsc, an RNAi therapeutic, targets PCSK9. Results were presented at the American Heart Association Scientific Sessions 2015.

Results from the study demonstrated a significant and clamped reduction in low-density lipoprotein-cholesterol (LDL-C) achieved over 180 days, as well as a decrease in the number of atherogenic lipids, including lipoprotein (a) and total cholesterol. Data revealed that the bi-annual subcutaneous dose administration of ALN-PCSsc led to an up to 53% maximal and 47% least squares mean reduction in LDL-C which was achieved at day 180, after a single, low volume injection. The candidate was generally well tolerated with no drug-related adverse events.

We remind investors that Alnylam has an exclusive global alliance with The Medicines Company for the development and commercialization of its ALN-PCS RNAi therapeutic program for the treatment of hypercholesterolemia. Per the terms of the agreement, as the candidate progresses to the phase II study, The Medicines Company will be responsible for its development.

The phase II (ORION-1) study on ALN-PCSsc is expected to begin by year end, while the phase III registration studies are expected to begin in 2017. The program will also include a study comparing ALN-PCSsc to anti-PCSK9 monoclonal antibodies (MAbs).

According to information provided by the company, about 34 million people in the U.S. suffer from hypercholesterolemia. Moreover, over 500,000 patients in the world are estimated to be affected by severe forms of hypercholesterolemia.

Other PCSK9 inhibitors in the market include Praluent, Repatha, Mevacor and Lipitor among others.

Alnylam and The Medicines Company both carry a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector are Flexion Therapeutics, Inc. FLXN and Corcept Therapeutics Incorporated CORT , both sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

MEDICINES CO (MDCO): Free Stock Analysis Report

ALNYLAM PHARMA (ALNY): Free Stock Analysis Report

CORCEPT THERAPT (CORT): Free Stock Analysis Report

FLEXION THERAPT (FLXN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CORT ALNY

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More